We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High Glucose Levels Predict Mortality in Pneumonia

By LabMedica International staff writers
Posted on 01 Oct 2012
Nondiabetic patients who have elevated serum glucose levels when they are admitted to the hospital with pneumonia have an increased risk of dying within 90 days. More...


Acute hyperglycemia associated with community-acquired pneumonia (CAP) can identify at-risk patients who need additional care to reduce their risk for mortality, compared with similar normoglycemic patients.

Scientists from the University Hospital of Saarland (Homburg, Germany) evaluated whether acute dysglycemia could predict a poor outcome in patients with CAP who had not been diagnosed with diabetes. They studied data from 6,891 adults with CAP who were enrolled in a prospective study from 2003 to 2009. The investigators also calculated various comorbidities for one month, three months and six months mortality on the basis of serum glucose levels at hospital admission. The majority of the patients were male, and the mean age was 60 years.

At the time of hospital admission, patients who had glucose levels from 6 to 11 mmol/L (108-198 mg/dL) were considered to have mild acute hyperglycemia and patients who had glucose levels of 14 mmol/L (252 mg/dL) or more were considered to have acute hyperglycemia. In all, 40% of CAP patients presented with hyperglycemia. An elevated glucose level at hospital admission was an independent predictor of one month, three months and six months mortality in CAP patients. In fact, increasing glucose levels corresponded to increasing risk for death from CAP.

Patients with mild to moderate hyperglycemia had a significantly higher hazard ratio (HR) for mortality at 90 days than patients with normal glucose levels at hospital admission. In patients presenting with acute hyperglycemia, HR increased to 6.04. In patients previously diagnosed with diabetes, there was no association between glucose level at admission and mortality. However, there was a nearly two-fold increased risk of dying in the 16% of patients with preexisting diabetes.

Philipp M. Lepper, MD, the senior investigator, said, "Increased serum glucose levels at admission are a risk factor for death among patients with community-acquired pneumonia. The risk for mortality starts to increase when serum glucose levels are slightly increased but remain below the defined threshold for overt diabetes." The study was presented on September 2, 2012, at the European Respiratory Society (ERS) 2012 Annual Congress held in Vienna Austria.

Related Links:

University Hospital of Saarland




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.